Bill....you are so right about Leqembi(and you spelled it right). It is certainly not been the blockbuster that Biogen/Eisai had anticipated. The plaque crowd has been letdown by the FDA and EMA. As I have pointed out in earlier posts, Biogen and Anavex have been going around since aducanumab and 2-73 went at each other(for Alzheimer's) in Anavex's MS evaluation in Biogen's lab years ago!
News 
Market Data 
Discover 
